Prigauro 150 mg injectable suspension
PDF Leaflet Revision Date: 10 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Endometriosis, contraception, endometrial and renal cancer.
Dosage (summary)
Endometriosis: 50 mg weekly or 100 mg every 2 weeks. Contraception: 150 mg every 3 months.
Special Populations
- Hepatic insufficiency
- Renal insufficiency
- Adolescents (12-18 years)
Pregnancy & Breastfeeding
Contraindicated in pregnancy; excreted in breast milk but no hazard to nursing child.
Key Drug Interactions
- Aminoglutethimide may depress bioavailability
- Metabolized by CYP450 3A4
Contraindications
- Known sensitivity to medroxyprogesterone acetate
- Undiagnosed vaginal bleeding
- Severe liver impairment
- Known or suspected pregnancy
Common side effects
- Menstrual irregularities
- Weight gain
- Headache
- Depression
- Fluid retention
Counselling Points
- Monitor for mood changes
- Inform about potential BMD loss
- Use additional contraception for STIs
Serious warnings
- Loss of bone mineral density
- Thromboembolic disorders
- Severe depression risk
Important Disclaimer
The Prigauro 150 mg injectable suspension professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
